AFT Pharmaceuticals says decision imminent on dual listing in NZ, Australia

Fiona Rotherham
Fri, 02 Oct 2015

By Fiona Rotherham Oct. 2 (BusinessDesk) - AFT Pharmaceuticals, a drugs developer and reseller,  has confirmed it’s close to making a final decision on a share-market listing first mooted in May. The Australian Financial Review's Street Talk column reported today that the Kiwi firm had kicked off informal investor briefings for a dual listing on the NZX and ASX, with First NZ Capital as an adviser and a value of $200 million to $300 million. AFT founder and majority shareholder Hartley Atkinson denied the reported valuation of the company...
Opinion
PATTRICK SMELLIE: What do the Nats do now?
Pattrick Smellie | Tue, 14 Jul 2020

Todd Muller's only job as National Party leader was to lose the election better than it seemed Simon Bridges was destined to do. Whoever replaces Muller has an even simpler task: save as much of th...

Listed Companies
Huljich family sells 25% of Pushpay stake
Dan Brunskill | Tue, 14 Jul 2020

The Huljich family has sold a quarter of its cornerstone stake in Pushpay Holdings, one of the rising software company stars. The 14.4 million shares were sold for $123.8 million, or $8.60 per shar...

Property
Housing market rebounds sharply; caution required
Jenny Ruth | Tue, 14 Jul 2020

The housing market bounded out of lockdown last month with sales volumes the highest for June in four years and prices nationally up 8.6 percent from a year earlier. The Real Estate Institute's lat...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.